In this review:
No benefit for adjuvant denosumab in early disease
Endocrine therapy only for HR+/HER2– disease and intermediate RS
Shorten adjuvant trastuzumab to 6 months?
Offer denosumab to postmenopausal HR+ patients on AIs?
Ribociclib + fulvestrant shows promise in HR+, HER2– advanced disease
Durvalumab + neoadjuvant chemotherapy in TNBC
Taselisib + fulvestrant in ER+, HER2–, PIK3CA-mutant disease
Addition of AZD5363 to first-line paclitaxel in TNBC
Sacituzumab govitecan in pre-treated HR+/HER2– metastatic disease
Real-world data on ribociclib + letrozole in ER+ disease
Please login below to download this issue (PDF)